Study on Glioblastoma Treatment with Metformin, Temozolomide, and Radiotherapy for Newly Diagnosed Patients

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of brain cancer called glioblastoma, which is a very aggressive form of cancer. The study will use a combination of treatments to see if they can help patients with this disease. The treatments being tested include a medication called Temozolomide, which is often used in cancer treatment, and Metformin, a drug commonly used to treat diabetes. In this study, Metformin will be used alongside radiotherapy, which is a treatment that uses high-energy rays to kill cancer cells.

The purpose of the study is to see if this combination of treatments can help patients live longer without the cancer getting worse. Patients who participate in the study will receive these treatments over a period of time, and their health will be monitored regularly. The study will look at how long patients live without the cancer progressing, as well as their overall survival and response to the treatment. Safety will also be closely monitored, including any side effects that may occur.

Participants will take the medications by mouth, and the study will follow them for several years to gather information on the effectiveness and safety of the treatment. The study aims to provide new insights into treating glioblastoma and potentially improve outcomes for patients with this challenging condition.

1 beginning of the trial

Upon joining the study, you will be required to provide a signed informed consent. This is a document that confirms your agreement to participate in the trial and that you understand the procedures involved.

You will undergo a series of initial assessments to ensure you meet the eligibility criteria. These assessments include blood tests to check your bone marrow, liver, and kidney functions, as well as a pregnancy test if applicable.

2 treatment initiation

The treatment phase begins with the administration of temozolomide and metformin hydrochloride. Temozolomide is provided in the form of 20 mg hard capsules, and metformin is provided as 500 mg film-coated tablets. Both medications are taken orally.

The dosage and frequency of these medications will be determined by your healthcare provider based on your specific condition and response to treatment.

3 radiotherapy

You will receive radiotherapy as part of your treatment plan. This is a type of cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.

The radiotherapy will be administered according to the Stupp protocol, which involves a total dose of 60 Gy. Your healthcare provider will explain the schedule and duration of the radiotherapy sessions.

4 ongoing assessments

Throughout the trial, you will have regular visits to monitor your health and the effectiveness of the treatment. These visits will include physical examinations, blood tests, and imaging studies as needed.

Your healthcare team will also monitor for any side effects or adverse reactions to the medications and radiotherapy. It is important to report any new symptoms or concerns during these visits.

5 end of treatment

At the end of the treatment phase, you will undergo a final assessment to evaluate the overall response to the therapy. This will include a review of your medical condition and any changes in your symptoms.

Your healthcare provider will discuss the results with you and outline any further steps or follow-up care that may be necessary.

Who Can Join the Study?

Sign a consent form to participate in the study. If you cannot sign it yourself, a legal representative can do it for you.
Have a newly-diagnosed glioblastoma (a type of brain tumor) that is confirmed by a lab test.
Be at least 18 years old.
Have a life expectancy of at least 16 weeks.
Be able to start radiation therapy within 7 weeks after diagnosis.
Have not received any treatment for glioblastoma other than surgery.
Have recovered well from surgery without major ongoing issues like infections.
Have adequate bone marrow function and normal liver function.
Have a creatinine clearance (a measure of kidney function) of at least 30 mL/min.
Have a white blood cell count of at least 2000/μL and neutrophils (a type of white blood cell) of at least 1500/μL.
Have platelets (cells that help with blood clotting) of at least 100,000/μL.
Have hemoglobin (a protein in red blood cells) of at least 9.0 g/dL.
Have serum creatinine (a waste product in the blood) of no more than 1.5 times the upper limit of normal.
Have AST and ALT (liver enzymes) levels no more than 3 times the upper limit of normal and total bilirubin no more than 1.5 times the upper limit of normal.
Be able to receive combined radiation and chemotherapy according to the Stupp protocol (a specific treatment plan).
Have an ECOG performance status of 0-2, which means you are fully active or have some symptoms but can take care of yourself.
If you are a woman of childbearing potential, have a negative pregnancy test before starting the study and agree to use contraception during the study and for 6 months after.
If you are a man, agree to use contraception if you are sexually active with a woman of childbearing potential during the study and for 6 months after.
Be affiliated with a health insurance system.
Be willing and able to follow the study protocol, including attending visits and undergoing tests.

Who Cannot Join the Study?

Patients with any other type of cancer besides glioblastoma grade 4 cannot participate.
Patients who have had another cancer in the past, unless it was treated and has not come back for at least 5 years, are excluded.
Patients with serious heart problems, such as heart failure or a recent heart attack, are not eligible.
Patients with uncontrolled high blood pressure cannot join the study.
Patients with severe liver or kidney disease are excluded.
Patients who are pregnant or breastfeeding cannot participate.
Patients who are unable to take oral medications are not eligible.
Patients with a known allergy to any of the study drugs cannot join.
Patients who have participated in another clinical trial within the last 30 days are excluded.
Patients with any condition that, in the opinion of the study doctor, makes participation unsafe are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
Hopitaux Universitaires Pitie Salpetriere	Paris	France
Hospital Foch	Suresnes	France
Centre Hospitalier Lyon Sud	Pierre Benite	France
Azbfapaprn Pzukasea Hiaiwyth Dr Portb	Paris	France

Trial status

Country	Status	Recruitment Start
France	Recruiting	01.04.2024

Trial locations

Investigated drugs:

Metformin is a medication commonly used to treat type 2 diabetes. In this clinical trial, it is being used to target a specific process in cancer cells called oxidative phosphorylation. The goal is to see if metformin can help improve the effectiveness of other cancer treatments by interfering with the energy production in cancer cells, potentially slowing down their growth.

Temozolomide is a type of chemotherapy drug that is used to treat certain brain cancers, including glioblastoma. It works by damaging the DNA of cancer cells, which can stop them from growing and dividing. In this trial, temozolomide is used alongside other treatments to see if it can help improve patient outcomes by further attacking the cancer cells.

Radiotherapy is a treatment that uses high-energy rays, like X-rays, to kill cancer cells. It is a common treatment for many types of cancer, including brain tumors. In this trial, radiotherapy is used in combination with other treatments to try to increase the chances of controlling the cancer and preventing it from coming back.

Investigated diseases:

Glioblastoma – Glioblastoma is a type of brain cancer that originates from glial cells, which support nerve cells in the brain. It is known for its aggressive nature and rapid growth. The disease typically begins in the cerebral hemispheres but can occur in other parts of the brain or spinal cord. As it progresses, glioblastoma can cause symptoms such as headaches, seizures, and neurological deficits, depending on the tumor’s location. The tumor infiltrates surrounding brain tissue, making it difficult to remove completely. Over time, it can lead to increased pressure within the skull, affecting brain function.

Trial ID:

2024-511026-31-01

Protocol code:

2019-0007

NCT ID:

NCT04945148

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Glioblastoma Treatment with Metformin, Temozolomide, and Radiotherapy for Newly Diagnosed Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?